In the kidney cancer group, the proportions of complete response (CR)/partial response (PR), and stable disease (SD)/progressive disease (PD) were 18.00 and 82.00% in the low LAIR‐1 expression group and 0.00 and 100.00% in the high LAIR‐1 expression group, correspondingly (p < 0.05) (Figure 8C). This evidence concerns the gene LAIR1 and kidney cancer.